- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02872272
Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population (AMIKACINE)
The loss of skin barrier function after burn causes increased susceptibility to infections, which are the leading cause of morbidity and mortality in burn patients. Topical antibiotics are one part of the therapeutic arsenal available to treat these infections. Pseudomonas aeruginosa and Staphylococcus aureus are the two major colonizing agents found in this population of patients.
The use of dressings impregnated with amikacin is a common practice. Actually, there are no available data on local and systemic effects with this antibiotic. The study of tissue and plasma pharmacokinetics of amikacin is therefore very important to secure and optimize this singular use of amikacin and improve the care of burn patients.
The objective of the study is to describe the plasma and tissue pharmacokinetics of amikacin after dermal administration and impregnated dressing to estimate the pharmacokinetic parameters and their variability in a burned population.
Secondary objectives are to assess on the one hand the relationship between the effectiveness of treatment and the concentration of antibiotic at the site of tissue infection, and on the other hand to assess the relationship between plasma concentration and the toxicity found of this treatment. We would like also to note the efficacy of the antibiotic treatment in terms of: need for repeat surgery (new skin graft), healing time and hospital length of stay.
Blood samples and skin biopsies will be made for each patient to day 3 and day 7 after the start of treatment.
The knowledge about the tissue concentrations obtained and a possible systemic absorption will then provide additional safety data and optimize the conditions of use of these dressings (dosage, frequency of administration) for effective treatment and safe.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Urielle DESALBRES, Director
- Phone Number: 04.91.38.27.47
- Email: drci@ap-hm.fr
Study Contact Backup
- Name: Sandrine WIRAMUS, PH
- Phone Number: 04.91.38.38.55
- Email: sandrine.wiramus@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- Assistance Publique Hopitaux De Marseille
-
Contact:
- Sandrine WIRAMUS, PH
- Phone Number: 04.91.38.38.55
- Email: sandrine.wiramus@ap-hm.fr
-
Principal Investigator:
- Sandrine WIRAMUS, PH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Skin infection of burn (whatever the surface, depth or location) supported by percutaneous administration of amikacin Age greater than 18 years Patient can be under guardianship or trusteeship Patient may present with cognitive impairment Patients receiving social coverage Patient who understood the objectives of the study, agreeing to participate in the study and who signed informed consent (or for which a trustee or guardian signed an informed consent if necessary) Patient mastering the French language
Exclusion Criteria:
minor patient or pregnant or lactating deprived of liberty patient Patient does not have insurance coverage Patient does not agreeing to participate in the study Patient allergic to amikacin or other antibiotic aminoglycosides
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with Amikacin
Dressing impregnated by administration of amikacin
|
Aminoglycosides.
Blood sampling for pharmacokinetic evaluation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of amikacin concentration
Time Frame: 24 months
|
Concentration of amikacin in nanograms per milliliter.
Circulating amikacin will be quantified by chromatographic high-performance technology
|
24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-09
- 2015-003972-64 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn Patients
-
Wake Forest UniversityWashington University School of Medicine; United States Department of Defense; University of North Carolina, Chapel HillTerminatedCritically Injured Burn PatientsUnited States
-
RWTH Aachen UniversityCompletedBurn Patients
-
Bispebjerg HospitalUnknownBurn Scar PatientsDenmark
-
Société des Produits Nestlé (SPN)CompletedEffect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn PatientsInfections on | Severe Burn PatientsFrance
-
Isra UniversityCompleted
-
Hospices Civils de LyonCompletedPatients With Massive Burn InjuryFrance
-
Shin Kong Wu Ho-Su Memorial HospitalCompletedPatients With Major Burn Injury in Formosa FunCost ExplosionTaiwan
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
-
Xequel Bio, Inc.United States Department of DefenseWithdrawnThermal Burn | Second Degree Burn
Clinical Trials on Treatment with Amikacin
-
Assistance Publique - Hôpitaux de ParisCompletedVentilator Associated PneumoniaFrance
-
University Medical Center GroningenRecruitingTuberculosisNetherlands
-
National Heart Institute, EgyptCompleted
-
Medical University of ViennaRecruitingChronic Skin UlcerAustria
-
Centre Hospitalier Intercommunal CreteilRecruitingUrinary Tract Infections | Urinary Tract Infections in ChildrenFrance
-
Insmed IncorporatedWithdrawn
-
Association Pour La Promotion A Tours De La Reanimation...UnknownVentilator Associated PneumoniaFrance
-
Cardeas PharmaCompletedHealthyUnited States
-
Insmed IncorporatedCompleted
-
Pontificia Universidad Catolica de ChileCompleted